- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00691509
Dietary Phytoestrogens, Complementary and Alternative Medicine, and Lifestyle in Predicting Survival of Women With Breast Cancer
The Role of Diet, Complementary Treatment and Lifestyle in Breast Cancer Survival
RATIONALE: Eating a diet rich in phytoestrogens may slow the growth of breast cancer cells and prevent further tumor progression. Learning about the lifestyles of women with breast cancer, their intake of phytoestrogens derived from food and supplements, and their use of complementary or alternative medicine (CAM) practices may help doctors learn more about breast cancer.
PURPOSE: This clinical trial is studying the effect of dietary and supplemental phytoestrogens and CAM therapies in preventing progression and improving survival of women with breast cancer.
Przegląd badań
Status
Warunki
Szczegółowy opis
OBJECTIVES:
- To determine if phytoestrogen intake affects breast cancer progression and survival in women with breast cancer.
- To consider the influence of other phytochemicals on breast cancer progression in these patients, using samples of patient blood and urine and patient-derived data.
- To develop a database of food, dietary supplements, and phytoestrogens based on data derived from these patients.
- To consider influences of diet and dietary supplements on quality of life of these patients.
- To measure 17 phytoestrogens in blood and urine samples from these patients.
OUTLINE: This is a multicenter study.
Patients undergo blood and urine sample collection once a year for 5 years during routine clinical follow-up after breast cancer diagnosis and treatment. Blood samples are frozen for future analysis of body hormones, tumor markers, and immune reactions, as well as vitamins and plant chemicals reflecting patient diet and supplements. Blood samples are also analyzed for genetic studies of cancer risk factors and polymorphisms. Urine samples are analyzed for the presence of phytoestrogens and their metabolites by immunoassays, high performance liquid chromatography (HPLC), and mass spectrometry. Some samples are analyzed for estrogenic potency by the estrogen receptor-mediated chemical activated luciferase gene expression test to assess total plasma levels of estrogen-mimics not previously detected by the other tests. Phytochemicals are also assessed.
Patients also complete a series of questionnaires once each year for 5 years and an EPIC 7-day Food Diary in years 2 and 4 to assess the role of diet and lifestyle in breast cancer survival. The questionnaires include the EORTC Quality of Life-30 to assess lifestyle; the General Health Questionnaire 12 to assess general health and levels of anxiety; and up to two Food Frequency questionnaires to assess habitual dietary intake of phytoestrogens. Patients are also asked about their use of dietary supplements and complementary and alternative medicine.
Typ studiów
Zapisy (Oczekiwany)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
England
-
London, England, Zjednoczone Królestwo, NW1 2BU
- Rekrutacyjny
- University College Hospital
-
Kontakt:
- Contact Person
- Numer telefonu: 44-207-679-9396
- E-mail: a.leathem@ucl.ac.uk
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
DISEASE CHARACTERISTICS:
Histologically confirmed invasive primary breast cancer
- Grade I to III disease
- No bilateral disease
- Completed active treatment for primary breast cancer within 9 months to 15 months after diagnosis
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Menopausal status not specified
- No prior cancer except basal cell carcinoma
- No other concurrent primary cancer
- No cognitive impairment
- No psychological problems (e.g., severe endogenous depression)
- Able to understand English well
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Plan studiów
Jak projektuje się badanie?
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
|---|
|
Przeżycie bez nawrotów
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Anthony Leathem, MD, University College London Hospitals
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Oczekiwany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- CDR0000589004
- UCLH-BCRG-DIETCOMPLYF-1456
- EU-20823
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .